In a recent development in patent law, the Federal Circuit is currently reviewing the Amgen Inc. V. Sandoz Inc, No. 2022-1147 case. The case pertains to matters related to patent obviousness and priority date.
As a backstory, Amgen, a large biopharmaceutical company, produces and markets a medication known as apremilast for treating specific types of psoriasis and psoriatic arthritis. This medication is commercialized under the brand name “Otezla.”
Turning to the details of the case, it is an appellate review. Specifically, the review focuses on the findings of the district court regarding the priority date – the determination of which party first invented the disputed product – and the issue of patent obviousness – a legal concept that refers to the measure of the predictability associated with the technical subject matter of a patent.
The outcome of this case could set significant precedents. This means that legal professionals must keep a close eye on the case. This is particularly critical for those working in companies that operate similarly to Amgen and Sandoz.
To stay updated on the case’s progression and understand its broader potential implications, follow the case’s reporting on JD Supra.